Lorz Laura Rojas, Kim Donghyun, Kim Mi-Yeon, Cho Jae Youl
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Heritage Material Research Team, Amorepacific R&D Unit, Yongin, Republic of Korea.
J Ginseng Res. 2020 May;44(3):453-460. doi: 10.1016/j.jgr.2019.02.003. Epub 2019 Feb 28.
BIOGF1K, a fraction of has desirable antimelanogenic, anti-inflammatory, and antiphotoaging properties that could be useful for treating skin conditions. Because its potential positive effects on allergic reactions in skin have not yet been described in detail, this study's main objective was to determine its efficacy in the treatment of atopic dermatitis (AD).
High-performance liquid chromatography was used to verify the compounds in BIOGF1K, and we used the (3-4-5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide method to determine its cytotoxicity in RBL-2H3 and HMC-1 cell lines. RBL-2H3 cells were induced using both anti-DNP-IgE/DNP-BSA and calcium ionophore (A2187) treatments, whereas HMC-1 cells were induced using A2187 alone. To measure mast cell degranulation, we performed histamine (enzyme-linked immunosorbent assay) and β-hexosaminidase assays. To quantify interleukin (IL)-4, IL-5, and IL-13 levels in RBL-2H3 cells, we performed quantitative polymerase chain reaction (PCR); to quantify expression levels of IL-4 and IL-13 in HMC-1 cells, we used semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Finally, we detected the total and phosphorylated forms of extracellular signal-regulated kinase, p-38, and c-Jun N-terminal kinase proteins by immunoblotting.
BIOGF1K decreased the AD response by reducing both histamine and β-hexosaminidase release as well as reducing the secretion levels of IL-4, IL-5, and IL-13 in RBL-2H3 cells and IL-4 and IL-13 in HMC-1 cells. In addition, BIOGF1K decreased MAPK pathway activation in RBL-2H3 and HMC-1 cells.
BIOGF1K attenuated the AD response, hence supporting its use as a promising and natural approach for treating AD.
BIOGF1K是一种具有理想的抗黑素生成、抗炎和抗光老化特性的成分，可用于治疗皮肤疾病。由于其对皮肤过敏反应的潜在积极作用尚未详细描述，本研究的主要目的是确定其治疗特应性皮炎（AD）的疗效。
采用高效液相色谱法验证BIOGF1K中的化合物，并使用（3-4-5-二甲基噻唑-2-基）-2-5-二苯基四氮唑溴盐法测定其对RBL-2H3和HMC-1细胞系的细胞毒性。RBL-2H3细胞用抗DNP-IgE/DNP-BSA和钙离子载体（A23187）处理诱导，而HMC-1细胞仅用A23187诱导。为了测量肥大细胞脱颗粒，我们进行了组胺（酶联免疫吸附测定）和β-己糖胺酶测定。为了量化RBL-2H3细胞中白细胞介素（IL）-4、IL-5和IL-13的水平，我们进行了定量聚合酶链反应（PCR）；为了量化HMC-1细胞中IL-4和IL-13的表达水平，我们使用了半定量逆转录聚合酶链反应（RT-PCR）。最后，我们通过免疫印迹检测细胞外信号调节激酶、p-38和c-Jun N端激酶蛋白的总形式和磷酸化形式。
BIOGF1K通过减少组胺和β-己糖胺酶释放以及降低RBL-2H3细胞中IL-4、IL-5和IL-13以及HMC-1细胞中IL-4和IL-13的分泌水平来减轻AD反应。此外，BIOGF1K降低了RBL-2H3和HMC-1细胞中MAPK途径的激活。
BIOGF1K减轻了AD反应，因此支持将其作为一种有前景的天然方法用于治疗AD。
